Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

We examined the effect of L-DOPA in the dose used for GH stimulation on the LH,FSH and Pr levels in 9 subjects with Turner syndrome, who had never received estrogens. We found the following (mean ...

Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...

Previous studies in a rat model of Parkinson disease (PD) have shown that dyskinesia induced by L-DOPA—a treatment-limiting adverse effect of long-term administration—is caused by the release ...

The use of this drug is limited by the development of psychiatric ... More information: Carina Plewnia et al, Rewarding properties of L-Dopa in experimental parkinsonism are mediated by sensitized ...

The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...

Researchers uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's drug levodopa.

Levodopa is the most efficacious agent for the treatment of motor features of Parkinson's disease but its chronic use is associated with the development of motor complications. Mounting evidence ...

NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...